Sign In
Last checked at 
30 Jun 2026 15:30
30 June 2026
CRISM Therapeutics Corporation
('CRISM', 'CRISM Therapeutics' or the 'Company')
Grant of Options
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has granted options over ordinary shares of no par value ('Ordinary Shares') in the Company (the 'Options') on 30 June 2026 to certain directors as set out below.
Director | Total number of Ordinary Shares subject to option grant | Options exercise price
|
Vesting Period
|
Andrew Webb | 504,000 | 10p | 30 June 2026 - 30 June 2028
|
Chris McConville | 408,798 | 10p | 30 June 2026 - 30 June 2028
|
Gerry Beaney | 99,999 | 10p | 30 June 2026 - 30 June 2028 |
The awards have been made under the Company's existing EMI Share Option Plan. The Options will vest as to one-third on grant, one-third on the first anniversary of grant and one-third on the second anniversary of grant. The options will become exercisable on the second anniversary of grant and expire on 30 June 2036, being 10 years from the date of grant.
The grant of Options to the Executive directors was overseen by the Remuneration Committee which made recommendations to the Board based on its assessment of each executive's personal performance during 2025 and 2026.
- Ends -
Enquiries:
Company | Nomad and Broker | Financial PR |
CRISM Therapeutics Corporation | S.P. Angel Corporate Finance LLP | Burson Buchanan |
Andrew Webb, Executive Chairman Chris McConville, CSO | David Hignell Vadim Alexandre Adam Cowl | Henry Harrison Topham Jamie Hooper CRISM@buchanancomms.co.uk |
via Burson Buchanan | +44 (0) 20 3470 0470 | +44 (0) 20 7466 5000 |
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.
For more information please visit: https://www.crismtherapeutics.com/
The Company's LEI is 213800XFW6MKVCHHPW88.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||||||||||||||
a)
| Name
| 1) Andrew Webb 2) Gerald Beaney 3) Chris McConville
| |||||||||||||||
2
| Reason for the notification
| ||||||||||||||||
a)
| Position/status
| 1) Executive Chairman 2) Non-Executive Director 3) Chief Scientific Officer
| |||||||||||||||
b)
| Initial notification /Amendment | Initial Notification | |||||||||||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||||||||
a)
| Name | CRISM Therapeutics Corporation | |||||||||||||||
b)
| LEI
| 213800XFW6MKVCHHPW88
| |||||||||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||||||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares with no par value | |||||||||||||||
Identification code | ISIN: VGG042401262
| ||||||||||||||||
b)
| Nature of the transaction
| Grant of Options | |||||||||||||||
c)
| Price(s) and volume(s) |
|
|
|
| ||||||||||||
d)
| Aggregated information | ||||||||||||||||
- Aggregated volume | N/A | ||||||||||||||||
- Price | N/A | ||||||||||||||||
e)
| Date of the transaction | 30 June 2026 | |||||||||||||||
f)
| Place of the transaction | Outside a trading venue | |||||||||||||||
Follow the stocks
